IMS HEALTH Forecasts 4.5 - 5.5 Percent Growth for Global Pharmaceutical Market in 2009, Exceeding $820 Billion

03-Nov-2008 - The global pharmaceutical market is expected to grow 4.5 - 5.5 percent next year, a pace similar to 2008, according to the IMS Global Pharmaceutical and Therapy Forecast™ released by IMS Health. The forecast predicts global pharmaceutical sales to surpass $820 billion in 2009, reflecting ...

Pfizer Names New Head of Clinical Development and Medical Affairs for Its Oncology Business Unit

27-Oct-2008 - Pfizer announced that it has named Mace L. Rothenberg, M.D. as Senior Vice President, Clinical Development and Medical Affairs for its Oncology Business Unit. Dr. Rothenberg comes to Pfizer from Vanderbilt where he was Professor of Medicine at the Vanderbilt University Medical Center and Ingram ...

Genentech Announces Phase III Study of Avastin Plus Chemotherapy in Adjuvant Colon Cancer Will Continue

23-Oct-2008 - Genentech, Inc. announced that it has been informed by the National Surgical Adjuvant Breast and Bowel Project (NSABP) that an ongoing Phase III study (NSABP C-08) of Avastin® (bevacizumab) plus chemotherapy in patients with early-stage colon cancer will continue as planned. The NSABP’s decision ...

Oncalis AG Licenses PI3K Inhibitors From ChemDiv Inc.

08-Oct-2008 - Oncalis AG (Oncalis), a privately-owned Swiss biotechnology company, and ChemDiv Inc. (ChemDiv), a privately-owned,California-based discovery services company announced that they entered into an exclusive agreement for a license to Oncalis a family of PI3K inhibitors. ONC-201, the first ...

CytRx Corporation Completes Acquisition of Innovive Pharmaceuticals, Inc.

Near-Term Commercialization Opportunities from Innovive’s Oncology Portfolio Complement CytRx Molecular Chaperone Pipeline and Technology Platform

25-Sep-2008 - CytRx Corporation announced the completion of its acquisition of Innovive Pharmaceuticals, Inc. CytRx purchased Innovive for total consideration of approximately 2.6 million shares of CytRx common stock, approximately $18.3 million of future performance-based milestone earn-outs, and the ...

First Published Study of New HPV Test for Developing Countries Shows High Accuracy in Predicting Cervical Disease

QIAGEN's careHPV test provides "substantially more accurate"

23-Sep-2008 - A new HPV (human papillomavirus) test developed by QIAGEN specifically for use in regions of the world with scarce resources is "substantially" more accurate in identifying women with cervical disease than the current methods (Pap testing and visual inspection) in these countries. The first ...

bioMerieux Gains Critical Oncology and Theranostics Capabilities with the Acquisition of Molecular Diagnostics Company AviaraDx

15-Sep-2008 - bioMérieux has acquired the privately held AviaraDx, Inc., a molecular in vitro diagnostics company, based in San Diego, California (USA). AviaraDx’s diagnostic tests, based on their proprietary technologies, are used in the molecular classification of cancers and to assist oncologists in making ...

Cyclacel appoints Nicholas Bacopoulos, Ph.D. to Board of Directors

12-Sep-2008 - Cyclacel Pharmaceuticals, Inc. announced the appointment of Nicholas Bacopoulos, Ph.D., to its Board of Directors. Dr. Bacopoulos has more than 25 years of experience at leading biotechnology and pharmaceutical companies, serving in multiple executive positions and managing the discovery and ...

Singapore's first commercial developer of molecular diagnostic assays commences operation

11-Sep-2008 - Dx Assays Pte Ltd, announced that it has officially started its operations. The company was established end 2007, as a joint venture between QIAGEN and Bio*One Capital. Dx Assays was formally launched at an opening ceremony attended by some 50 guests. Dx Assays will develop and validate ...

Elan and Biogen Idec Initiate First Clinical Trial of TYSABRI in Oncology

08-Sep-2008 - Elan Corporation, plc and Biogen Idec announced the initiation of the first clinical trial of TYSABRI® (natalizumab) in oncology. The first dose of TYSABRI was administered in the trial. The objectives of this Phase I/II study are to evaluate the safety and potential anti-tumor activity of ...